Table 2 Potential epigenetic chemotherapies for oropharyngeal carcinoma
Chemotherapeutic Agent | Status | Reference |
|---|---|---|
DNMT inhibitors | ||
 Arsenic trioxide | Clinical Trials | [112] |
 5- azacytidine (Vidaza, Celgene) | USFDA Approved | [47] |
 5-aza-2′-deoxycitidine (Decitabine, Dacogen, SuperGen) | USFDA Approved | [47] |
 MG98 | Clinical trials | [122] |
HDAC inhibitors | ||
 LAQ-824/LBH 589 (Farydak, panobinostat) | USFDA Approved | [122] |
 PXD-101(Belinostat) | Clinical trials | [122] |
 Valproic acid (Mg valproate) | Clinical trials | [122] |
 Suberoylanilide hydroxamic acid (vorinostat, SAHA) | USFDA Approved | [122] |
 FK-228 (romidepsin) | USFDA Approved | [121] |
 Phenylbutyrate | Clinical trials | [122] |
 MS-275 (entinostat) | Clinical trials | |
 CI-994 | Clinical trials | |
 MGCD-0103 (Mocetinostat) | Clinical trials | [145] |
 JNJ-26481585 (Quisinostat) | Clinical trials | |
HMT inhibitors | ||
 EPZ-6438 (E7438, Epizyme) | Clinical trials | |
 3-Deazaneplanocin (DZNep) | Clinical trials | [58] |
 EPZ-5676 | Clinical trials | [62] |
 EPZ-5687 | Preclinical | [58] |
 GSK-343 | Preclinical | [58] |